Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair.
Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair.
复制标题
DOI：
10.1186/ar3142
复制
发表时间：
2010
影响因子：
4.9
通讯作者：
Mochida J
中科院分区：
文献类型：
--
作者：
Nagai T;Sato M;Kutsuna T;Kokubo M;Ebihara G;Ohta N;Mochida J
在这项研究中，我们研究了贝伐单抗（一种人源化单克隆抗血管内皮生长因子（VEGF）抗体）对兔膝关节骨软骨缺损的修复效果。将20只日本白兔髌骨沟造骨软骨缺损，分为两组：B组，给予贝伐单抗（手术当日和2周后静脉注射100 mg），对照组（仅缺损）。术后1、3个月处死家兔。切片用红花红O染色，采用改良的O’driscoll国际软骨修复学会分级系统对修复部位进行评估。采用免疫组化分析评估软骨调节素(ChM)- 1和VEGF的表达。术后1个月，B组修复部位填充软骨组织。3个月时，修复部位保留了这种软骨表型。对照组1个月时，缺损主要由纤维组织填充。3个月时，缺损被纤维组织和骨取代。在3个月的时间里，B组的组织学评分明显高于对照组。1个月时，B组修复组织底部ChM-I呈强烈阳性。在同一区域也发现了VEGF。在对照组中，修复组织中未观察到chm - 1。相反，重塑增生性软骨细胞层强烈染色VEGF。静脉注射贝伐单抗有助于骨软骨缺损模型中关节软骨的更好修复。我们建议使用抗vegf抗体促进关节软骨修复的可能性，而不是使用培养细胞或人工支架。
In this study, we investigate the efficacy of repairing an osteochondral defect in rabbit knee joints by administering bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody. An osteochondral defect was created on the patellar groove of 20 Japanese white rabbits that were classified into two recipient groups: group B, administration of bevacizumab (100-mg intravenous injection on the day of surgery and 2 weeks later), and a control group (defect only). Rabbits were killed 1 and 3 months postoperatively. Sections were stained with safranin O. Repair sites were evaluated using the modified O'Driscoll International Cartilage Repair Society grading system. The expression of chondromodulin (ChM)-I and VEGF was evaluated using immunohistochemical analyses. At 1 month postoperatively, the repair site in group B was filled with cartilaginous tissue. At 3 months, the repair site retained this cartilage phenotype. At 1 month in the controls, the defects were mainly filled with fibrous tissue. At 3 months, the defect was replaced by fibrous tissue and bone. Over the 3-month period, histological scores were significantly higher in group B than in the controls. At 1 month, group B showed intense positive results for ChM-I in the bottom of the repair tissue. VEGF was also identified in the same area. In the controls, no ChM-I was observed in the repair tissue. Conversely, the remodeling hypertrophic chondrocyte layer stained intensely for VEGF. Intravenous administration of bevacizumab contributes to better repair of articular cartilage in an osteochondral defect model. We suggest the possibility of facilitating articular cartilage repair with anti-VEGF antibody rather than using cultured cells or artificial scaffolds.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
--
作者：
Kubo, Seiji;Cooper, Gregory M.;Matsumoto, Tomoyuki;Phillippi, Julie A.;Corsi, Karin A.;Usas, Arvydas;Li, Guangheng;Fu, Freddie H.;Huard, Johnny
通讯作者：
Huard, Johnny
影响因子：
158.5
作者：
Hurwitz, H;Fehrenbacher, L;Kabbinavar, F
通讯作者：
Kabbinavar, F
DOI：
10.1083/jcb.110.3.753
发表时间：
1990-03
期刊：
The Journal of cell biology
影响因子：
--
作者：
Gonzalez AM;Buscaglia M;Ong M;Baird A
通讯作者：
Baird A
影响因子：
4.8
作者：
Hiraki, Y;Inoue, H;Kondo, J
通讯作者：
Kondo, J